Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

Uno studio in aperto per valutare la sicurezza, l'efficacia e la cinetica cellulare di YTB323 nelle malattie autoimmuni gravi e refrattarie

14 ottobre 2026 aggiornato da: Novartis Pharmaceuticals

Uno studio in aperto, multicentrico, di fase 1/2 per valutare la sicurezza, l'efficacia e la cinetica cellulare di YTB323 nei partecipanti con disturbi autoimmuni gravi e refrattari

The study is intended to assess safety, efficacy and cellular kinetics of YTB323 treatment in participants with severe refractory systemic lupus erythematosus.

Panoramica dello studio

Stato

Completato

Intervento / Trattamento

Tipo di studio

Interventistico

Iscrizione (Effettivo)

21

Fase

  • Fase 2
  • Fase 1

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Luoghi di studio

    • Victoria
      • Clayton, Victoria, Australia, 3168
        • Novartis Investigative Site
      • Paris, Francia, 75013
        • Novartis Investigative Site
      • Pessac, Francia, 33604
        • Novartis Investigative Site
      • Strasbourg, Francia, 67091
        • Novartis Investigative Site
      • Mainz, Germania, 55131
        • Novartis Investigative Site
    • Baden-Wurttemberg
      • Freiburg im Breisgau, Baden-Wurttemberg, Germania, 79106
        • Novartis Investigative Site
      • Barcelona, Spagna, 08035
        • Novartis Investigative Site
      • Madrid, Spagna, 28009
        • Novartis Investigative Site
      • Bern, Svizzera, 3010
        • Novartis Investigative Site
      • Lausanne, Svizzera, 1011
        • Novartis Investigative Site

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

Da 18 anni a 65 anni (Adulto, Adulto più anziano)

Accetta volontari sani

No

Sessi ammissibili allo studio

Tutto

Descrizione

Inclusion Criteria:

  • Signed informed consent
  • Adequate renal, hepatic, cardiac, hematological and pulmonary function
  • Men and women with SLE, aged ≥18 years and ≤65 years at screening, fulfilling the 2019 European League Against Rheumatism EULAR/ACR classification criteria for SLE.
  • Patient must be positive for at least one of the following autoantibodies at screening: antinuclear antibodies (ANA) at a titer of ≥1:80, or anti dsDNA (above the ULN); or anti-Sm (above the ULN)
  • Active (severe) disease as defined by SLEDAI-2K ≥ 8 (not including the SLEDAI-2K domains of lupus headache, cerebrovascular accident, organic brain syndrome) and at least one of the following significant SLE related organ involvements:
  • Renal
  • At least moderate or severe peri/myocarditis
  • At least moderate or severe pleuritis or other lung involvement
  • Vasculitis
  • Failure to respond to two or more standard immunosuppressive therapies (including one of mycophenolate or cyclophosphamide), unless contraindicated or having experienced documented adverse events or intolerance related to such immunosuppressive drugs not allowing their further use, in combination with glucocorticoids and failure to respond to at least one biological agent (unless contraindicated, the patient deemed ineligible by the Investigator or not available in a country).

Exclusion Criteria:

  • Clinically significant active, opportunistic, chronic or recurrent infection confirmed by clinical evidence, imaging, or positive laboratory tests (e.g., blood cultures, PCR for DNA/RNA, such as COVID-19 etc.) one month prior to or during screening. Patients who have had at least one severe infection that required prolonged hospitalization in the intensive care setting within 5 years prior to screening and/or at least one severe infection that required prolonged hospitalization within one year prior to screening.
  • Uncontrolled diabetes mellitus, lung diseases or any other illness that are not related to SLE that in the opinion of the Investigator would jeopardize the ability of the patient to tolerate lymphodepletion and CD19 CAR-T cell therapy
  • Prior history of malignancy except for localized basal cell or squamous skin cancer. Other malignancies for which the patient is judged to be cured by local surgical therapy, such as head and neck cancer, or stage I breast cancer will be considered on an individual basis
  • Any patients requiring medications prohibited by the protocol
  • Any psychiatric condition or disability making compliance with treatment or informed consent impossible
  • Prior treatment with anti-CD19 therapy, adoptive T cell therapy or any prior gene therapy product (e.g. CAR-T cell therapy)
  • History of bone marrow/hematopoietic stem cell or solid organ transplantation
  • Female participants who are pregnant or breastfeeding, or intending to conceive during the course of the study
  • Women of childbearing potential, defined as all women physiologically capable of becoming pregnant, unless they are using a highly effective method of contraception starting from the time of enrollment to at least 12 months after the YTB323 infusion (or longer if required as per local regulations) and until CAR-T cells are no longer present by qPCR on two consecutive tests
  • Sexually active males unwilling to use a condom during intercourse from the time enrollment for at least 12 months after the YTB323 infusion and until CAR-T cells are no longer present by qPCR on two consecutive tests
  • Any acute, severe lupus related flare during screening that needs immediate treatment and/or makes the immunosuppressive washout impossible; thus, makes the patient ineligible for CD19 CAR-T therapy as judged by the Investigator, such as acute central nervous system (CNS) lupus (e.g. psychosis, epilepsy) or catastrophic antiphospholipid syndrome
  • Significant, likely irreversible organ damage related to SLE, e.g. end stage renal disease, that in the opinion of the Investigator renders CD19 CAR-T cell therapy would be unlikely to benefit the patient
  • B cell aplasia

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Scopo principale: Trattamento
  • Assegnazione: N / A
  • Modello interventistico: Assegnazione di gruppo singolo
  • Mascheramento: Nessuno (etichetta aperta)

Armi e interventi

Gruppo di partecipanti / Arm
Intervento / Trattamento
Sperimentale: YTB323

Single infusion of YTB323

Single infusion of YTB323

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Number of participants with AEs and SAEs
Lasso di tempo: Day 1 to 2 years

Long term safety follow up

Day 1 to 2 years

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
CAR transgene levels by quantitative polymerase chain reaction (qPCR) in blood (Maximum observed blood concentration Cmax)
Lasso di tempo: Pre-dose, up to 2 years

Blood samples will be collected to assess cellular kinetics.

Pre-dose, up to 2 years
CAR transgene levels by quantitative polymerase chain reaction (qPCR) in blood (Area under plasma concentration -time AUC)
Lasso di tempo: Pre-dose, up to 2 years

Blood samples will be collected to assess cellular kinetics.

Pre-dose, up to 2 years
CAR transgene levels by quantitative polymerase chain reaction (qPCR) in blood (Time to reach maximum concentration Tmax)
Lasso di tempo: Pre-dose, up to 2 years

Blood samples will be collected to assess cellular kinetics.

Pre-dose, up to 2 years
CAR transgene levels by quantitative polymerase chain reaction (qPCR) in blood (Terminal elimination half-life T1/2)
Lasso di tempo: Pre-dose, up to 2 years

Blood samples will be collected to assess cellular kinetics.

Pre-dose, up to 2 years
CAR transgene levels by quantitative polymerase chain reaction (qPCR) in blood (Last measurable concentration Clast)
Lasso di tempo: Pre-dose, up to 2 years

Blood samples will be collected to assess cellular kinetics.

Pre-dose, up to 2 years
CAR transgene levels by quantitative polymerase chain reaction (qPCR) in blood (Time to reach last measurable concentration Tlast)
Lasso di tempo: Pre-dose, up to 2 years

Blood samples will be collected to assess cellular kinetics.

Pre-dose, up to 2 years
Number of patients with anti-drug antibodies
Lasso di tempo: Pre-dose, up to 2 years

Blood samples will be collected to measure anti-drug antibodies against YTB323.

Pre-dose, up to 2 years
Level of T cell activation by YTB323
Lasso di tempo: Pre-dose, up to 2 years

Blood samples will be collected to measure the level of T cell activation by YTB323.

Pre-dose, up to 2 years
Number of patients infused with planned target dose
Lasso di tempo: Day 1

Feasibility of the manufacturing process in autoimmune disorders.

Day 1
Change from pre-dose up to 2 years in the Systemic Lupus Erythematosus Disease Activity Index-2000 (SLEDAI-2K) score
Lasso di tempo: Pre-dose, up to 2 years

SLEDAI-2K scores are between 0 and 105, a higher score represents a higher disease activity.

Pre-dose, up to 2 years
Change from pre-dose up to 2 years in Physician's global assessment (PGA)
Lasso di tempo: Pre-dose, up to 2 years

The Physician's Global assessment is a visual analog scale from 0 to 3, 0 represents no activity and 3 represents severe disease activity.

Pre-dose, up to 2 years
Change from pre-dose up to 2 years in Lupus Low Disease Activity State (LLDAS)
Lasso di tempo: Pre-dose, up to 2 years

LLDAS is a composite measure based on: SLEDAI-2K ≤ 4, with no activity in major organ system (renal, central nervous system, cardiopulmonary, vasculitis, and fever) and no hemolytic anemia or gastrointestinal activity, current, no new lupus disease activity compared with the previous assessment, prednisone (or its equivalent) dose ≤ 7.5 mg/day, PGA (scale 0-3) ≤ 1, well tolerated standard maintenance doses of immunosuppressive lupus therapy.

Pre-dose, up to 2 years
Remission rate
Lasso di tempo: Up to 2 years

Remission as specified by Definitions Of Remission In Systemic Lupus Erythematosus (DORIS) criteria: Clinical SLEDAI=0, PGA<0.5 (0-3) irrespective of serology.

The patient may be on antimalarials, low-dose glucocorticoids (prednisolone ≤5 mg/day), and/or stable immunosuppressive therapy including biologics.

Up to 2 years
Change from pre-dose up to 2 years in Urinary protein creatinine ratio (UPCR)
Lasso di tempo: Pre-dose, up to 2 years

Change in the value of UPCR.

Pre-dose, up to 2 years
Incidence of Complete renal response (CRR)
Lasso di tempo: Up to 2 years

Number of participants who achieved CRR.

Up to 2 years

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Investigatori

  • Direttore dello studio: Novartis Pharmaceuticals, Novartis Pharmaceutical

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Effettivo)

28 febbraio 2023

Completamento primario (Effettivo)

24 settembre 2026

Completamento dello studio (Effettivo)

24 settembre 2026

Date di iscrizione allo studio

Primo inviato

27 febbraio 2023

Primo inviato che soddisfa i criteri di controllo qualità

22 marzo 2023

Primo Inserito (Effettivo)

4 aprile 2023

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

15 ottobre 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

14 ottobre 2026

Ultimo verificato

1 ottobre 2026

Maggiori informazioni

Termini relativi a questo studio

Piano per i dati dei singoli partecipanti (IPD)

Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?

SÌ

Descrizione del piano IPD

Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.

This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

Sì

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

No

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .

Sottoscrivi